Chronic myeloid leukemia (CML) is a myeloproliverative neoplasia that is characterized by overproduction of cells of the myeloid lineage. Disease course consists of three phases: chronic phase (CP), acceleration phase (AP), and blast crisis (BC). Hallmark of the disease is the fusion of BCR...
which produces blood cells. "Myelogenous" refers to the type of blood cells this leukemia affects. "Chronic" means this cancer is more slowly progressing than other severe forms of leukemia.
chronic myeloid leukemiaclonal evolutiondasatinibimatinib failurenilotinibresistance mutantstransplantationINTRODUCTION: failure represents a major clinical challenge in the management of .: Definition of failure, its causes, the various approaches to the treatment of failure such as dose escalation, second-...
This 45-page report provides a behind-the-scenes look at the treatment experience for those living with Chronic Myeloid Leukemia (CML). Using detailed quantitative data, it gives a full picture of the CML treatment story -...
Eiring AM, Khorashad JS, Morley K, Deininger MW. Advances in the treatment of chronic myeloid leukemia. BMC Med. 2011;9:99.Eiring AM, Khorashad JS, Morley K, Deininger MW. Advances in the treatment of chronic myeloid leukemia. BMC Med 2011; 9: 99....
The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution to...
DIAGNOSTIC AND TREATMENT FOR CHRONIC AND ACUTE PHASE MYELOID LEUKEMIADIAGNOSTIC AND TREATMENT FOR CHRONIC AND ACUTE PHASE MYELOID LEUKEMIADisclosed are methods of predicting responsiveness of a cancer cell to a tyrosine kinase inhibitor, and methods of predicting the risk of progression of a cancer cell...
Background: Imatinib mesylate (Glivec,Novartis), an inhibitor of Bcr-abl tyrosine kinase, is currently being used in the treatment of CML with hematological, cytogenetic and molecular response. In Brazil, this drug is approved by Health Department for chronic phase (CP) as a second line drug ...
of tyrosine kin- ase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Canc... Breccia,Alimena 被引量: 0发表: 0年 Advances in the treatment of chronic myeloid leukemia Although imatinib is firmly established as an...
Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder induced by translocation of chromosomes 9 and 22, resulting in an overproduction of myeloid blood cells. CML-specific characteristics include a latency time of several years, a period of coexistence of malignant and normal cells and ...